Cellex Biosciences Inc. has received a $500,000 Phase II smallbusiness innovation research grant (SBIR) from the NationalCancer Institute to adapt the company's Oxycell bioreactor intoits commercial-scale protein production system, Acusyst.

The Minneapolis company (NASDAQ: CLXX) provides cellprocessing products and services.

(c) 1997 American Health Consultants. All rights reserved.